Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
| REGENERON PHARMACEUTICALS, INC. |
| MYLAN PHARMACEUTICALS INC., BIOCON BIOLOGICS INC. and AMGEN USA, INC. |
| 24-1402 |
| January 30, 2024 |
| U.S. Court of Appeals, Federal Circuit |
| Patent Infringement (Fed. Qst.) |
Opinions
We have the following opinions for this case:
| Description |
|---|
| REGENERON PHARMACEUTICALS, INC. v. MYLAN PHARMACEUTICALS INC. |
Docket Report
RSS Track this Docket
This docket was last retrieved on March 26, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 19 NOTICE OF NON-COMPLIANCE: The submissions of Appellant Regeneron Pharmaceuticals, Inc. and Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc., Response [ # 18 ], [17], [ # 16 ], are not in compliance with the rules of this court (see attached). Compliant document due on 04/02/2024. Service as of this date by the Clerk of Court. [992893] [JSP] [Entered: 03/26/2024 08:59 AM] |
| Filing 18 RESPONSE of Appellant Regeneron Pharmaceuticals, Inc. to Doc. No. [ # 15 ], [ # 15 ], [ # 15 ]. Service: 03/25/2024 by email. [992879] [24-1402] This document is non-compliant. See Doc No.[ # 19 ] [David Berl] [Entered: 03/25/2024 10:50 PM] |
| Filing 17 Confidential Defendants-Cross-Appellants' Response to Order to Show Cause filed by Cross-Appellants Mylan Pharmaceuticals Inc. and Biocon Biologics Inc. corresponding to Doc. No. [ # 16 ]. Service: 03/25/2024 by email. [992876] [24-1402] This document is non-compliant. See Doc No.[ # 19 ] [Deanne Mazzochi] [Entered: 03/25/2024 07:41 PM] |
| Filing 16 RESPONSE of Cross-Appellants Mylan Pharmaceuticals Inc. and Biocon Biologics Inc. to Doc No. [ # 15 ], [ # 15 ], [ # 15 ]. Service: 03/25/2024 by email. [992874] [24-1402] This document is non-compliant. See Doc No.[ # 19 ] [Deanne Mazzochi] [Entered: 03/25/2024 06:56 PM] |
Filing 15
ORDER filed staying briefing schedule pending further notice of the court. Within 30 days from the date of entry of this order, the parties are directed to show cause why these appeals should not be dismissed for lack of jurisdiction. Service as of this date by the Clerk of Court. [985902] [NL] [Entered: 02/22/2024 05:02 PM]
|
| Filing 14 Corrected Docketing Statement for the Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/22/2024 by email. [985837] [24-1402] [David Berl] [Entered: 02/22/2024 03:52 PM] |
| Filing 13 Corrected Certificate of Interest for Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/22/2024 by email. [985835] [24-1402] [David Berl] [Entered: 02/22/2024 03:49 PM] |
| Filing 12 Corrected Entry of Appearance for David I. Berl; Thomas F. Fletcher; Andrew V. Trask; Shaun P. Mahaffy; Kathryn S. Kayali; Arthur J. Argall; Adam Pan; Rhochelle Krawetz as counsel for Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/22/2024 by email. [985834] [24-1402] [David Berl] [Entered: 02/22/2024 03:44 PM] |
| Filing 11 NOTICE OF NON-COMPLIANCE: The submission of Appellant Regeneron Pharmaceuticals, Inc., Entry of Appearance, Docketing Statement, Certificate of Interest [ # 10 ], [ # 9 ], [ # 7 ], is not in compliance with the rules of this court (see attached). Compliant document due on 02/22/2024. Service as of this date by the Clerk of Court. [983802] [IMH] [Entered: 02/14/2024 12:16 PM] |
| Filing 10 Certificate of Interest for Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/13/2024 by email. [983661] [24-1402] This document is non-compliant. See Doc No. [ # 11 ] [David Berl] [Entered: 02/13/2024 11:58 PM] |
| Filing 9 Entry of Appearance for David I. Berl; Ellen E. Oberwetter; Thomas S. Fletcher; Andrew V. Trask; Shaun P. Mahaffy; Kathryn S. Kayali; Arthur J. Argall; Adam Pan; Rhochelle Krawetz as counsel for Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/13/2024 by email. [983660] [24-1402] This document is non-compliant. See Doc No. [ # 11 ] [David Berl] [Entered: 02/13/2024 11:55 PM] |
| Filing 8 Notice of Related Case Information for Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/13/2024 by email. [983659] [24-1402] [David Berl] [Entered: 02/13/2024 11:53 PM] |
| Filing 7 Docketing Statement for the Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/13/2024 by email. [983658] [24-1402] This document is non-compliant. See Doc No. [ # 11 ] [David Berl] [Entered: 02/13/2024 11:50 PM] |
| Filing 6 Notice of Related Case Information for Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc.. Service: 02/13/2024 by email. [983656] [24-1402] [William Rakoczy] [Entered: 02/13/2024 10:35 PM] |
| Filing 5 Certificate of Interest for Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc.. Service: 02/13/2024 by email. [983654] [24-1402] [William Rakoczy] [Entered: 02/13/2024 10:31 PM] |
| Filing 4 Docketing Statement for the Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc.. Service: 02/13/2024 by email. [983653] [24-1402] [William Rakoczy] [Entered: 02/13/2024 10:22 PM] |
| Filing 3 Entry of Appearance for William A. Rakoczy; Heinz J. Salmen; Paul J. Molino; Deanne M. Mazzochi; Eric R. Hunt; Lauren M. Lesko; Neil B. McLaughlin as counsel for Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc.. Service: 02/13/2024 by email. [983652] [24-1402] [William Rakoczy] [Entered: 02/13/2024 10:18 PM] |
| Filing 2 Note to File: The following cases are consolidated: 24-1402 Lead with 24-1405 Cross-Appeal. The parties must file all documents in the lead appeal only. [980279] [24-1402, 24-1405] [JSP] [Entered: 01/30/2024 10:37 AM] |
| Filing 1 Appeal docketed. Received: 01/29/2024. [980267] Entry of Appearance is due on 02/13/2024. Certificate of Interest is due on 02/13/2024. Docketing Statement is due on 02/13/2024. Appellant's brief is due on 04/01/2024. [JSP] [Entered: 01/30/2024 10:16 AM] |
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
